E2814 (Etalanetug) Anti-Tau Therapy

Overview

E2814 (etanlanetug) is an anti-tau monoclonal antibody developed by [Eisai Co., Ltd.](https://www.eisai.com/) that specifically targets the microtubule-binding region (MTBR) of tau protein. This represents a novel approach in tau-targeted therapy, as most previous anti-tau antibodies targeted the N-terminus of tau, which showed limited efficacy in clinical trials. E2814 is the first MTBR-targeting antibody to advance to late-stage clinical testing.

Mechanism of Action

Tau Biology and Pathological Relevance

Tau protein is a microtubule-associated protein that stabilizes axonal microtubules in neurons. In Alzheimer's disease and other tauopathies, tau becomes abnormally hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads throughout the brain in a characteristic pattern.

The tau protein has several key regions:

flowchart TD
A["Tau protein"] --> B["N-terminal region"]
A --> C["Proline-rich region"]
A --> D["Microtubule-binding region (MTBR)"]
A --> E["C-terminal region"]

D --> D1["3R tau"]
D --> D2["4R tau"]

B --> B1["Anti-tau antibodies vs N-terminus<br/>(gosuranemab, tilavonemab) - failed Phase 2"]
D --> D3["Anti-tau antibodies vs MTBR<br/>(E2814, bepranemab) - novel approach"]

E2814 Binding Specificity

E2814 binds to tau aggregates in the brain and specifically targets the MTBR region, particularly:

Overview

E2814 (etanlanetug) is an anti-tau monoclonal antibody developed by [Eisai Co., Ltd.](https://www.eisai.com/) that specifically targets the microtubule-binding region (MTBR) of tau protein. This represents a novel approach in tau-targeted therapy, as most previous anti-tau antibodies targeted the N-terminus of tau, which showed limited efficacy in clinical trials. E2814 is the first MTBR-targeting antibody to advance to late-stage clinical testing.

Mechanism of Action

Tau Biology and Pathological Relevance

Tau protein is a microtubule-associated protein that stabilizes axonal microtubules in neurons. In Alzheimer's disease and other tauopathies, tau becomes abnormally hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads throughout the brain in a characteristic pattern.

The tau protein has several key regions:

flowchart TD
A["Tau protein"] --> B["N-terminal region"]
A --> C["Proline-rich region"]
A --> D["Microtubule-binding region (MTBR)"]
A --> E["C-terminal region"]

D --> D1["3R tau"]
D --> D2["4R tau"]

B --> B1["Anti-tau antibodies vs N-terminus<br/>(gosuranemab, tilavonemab) - failed Phase 2"]
D --> D3["Anti-tau antibodies vs MTBR<br/>(E2814, bepranemab) - novel approach"]

E2814 Binding Specificity

E2814 binds to tau aggregates in the brain and specifically targets the MTBR region, particularly:

• p-tau396/404: Phosphorylated tau at positions 396 and 404
• p-tau217: Another key phosphorylation site in the MTBR
• MTBR residues 244-368: Core region involved in tau filament formation

Comparison with Previous Anti-Tau Approaches

| Target Region | Antibody | Company | Result |
|---------------|----------|---------|--------|
| N-terminus | Gosuranemab | Roche | Failed Phase 2 |
| N-terminus | Tilavonemab | AbbVie | Failed Phase 2 |
| N-terminus | Zagotenemab | Eli Lilly | Failed Phase 2 |
| N-terminus | Semorinemab | Roche | Failed Phase 2 |
| MTBR | E2814 | Eisai | Phase 2/3 |
| MTBR | Bepranemab | UCB | Phase 2 |

The failures of N-terminal targeting antibodies demonstrated that not all tau epitopes are suitable for therapeutic targeting. The MTBR, being the structural core of tau filaments, represents a more direct target.

Clinical Development

Phase 1 Studies

First-in-Human Study (E2814-001)

The Phase 1 study (NCT04622375) was a first-in-human trial evaluating the safety, tolerability, pharmacokinetics, and target engagement of E2814.

Key Findings:

• Safety profile: E2814 was well-tolerated at all doses tested
• Dose-dependent engagement: Clear dose-dependent relationship between drug exposure and CSF tau changes
• CSF tau reduction: Significant reduction in CSF tau levels at higher doses
• Brain target engagement: Evidence of tau engagement in the brain via PET imaging

• Multiple ascending dose cohorts
• Intravenous administration
• Doses ranging from low to high mg/kg

Phase 1b Study

Additional Phase 1 studies in healthy volunteers and patients established:

• Pharmacokinetics: Suitable half-life for IV dosing
• Pharmacodynamics: Biomarker changes consistent with target engagement
• Dose selection: Rationale for Phase 2 dose selection

Phase 2/3 Trials

DIAN-TU Study

E2814 is being evaluated in the DIAN-TU (Dominantly Inherited Alzheimer Network Trials Unit) study, which focuses on individuals with autosomal dominant Alzheimer's disease.

| Trial | Phase | Status | NCT Number | Population |
|-------|-------|--------|------------|------------|
| E2814-001 | Phase 1 | Completed | NCT04622375 | Healthy volunteers, early AD |
| DIAN-TU-001 | Phase 2/3 | Active | NCT05256190 | Autosomal dominant AD |

DIAN-TU Background:

• Genetic form of AD caused by deterministic mutations (APP, PSEN1, PSEN2)
• Predictable age of onset allows pre-symptomatic intervention
• Multiple arms testing different disease-modifying therapies
• Gold standard for testing prevention approaches in AD

• Randomized, double-blind, placebo-controlled
• Pre-symptomatic and early-symptomatic carriers
• Primary endpoint: Clinical and biomarker outcomes
• Long-term follow-up for safety and efficacy

Tau PET Imaging

E2814 development includes advanced tau imaging:

• Tau PET ligands: Use of flortaucipir and next-generation tau tracers
• Regional analysis: Assessment of tau burden in specific brain regions
• Treatment effects: Evaluation of tau PET changes over time
• Correlation with clinical outcomes: Linking imaging to cognitive measures

Target Engagement and Biomarkers

Cerebrospinal Fluid Biomarkers

Key CSF biomarkers being monitored:

| Biomarker | What It Measures | Expected Change |
|-----------|------------------|------------------|
| Total tau | Overall tau pathology | Reduction |
| Phosphorylated tau (p-tau181, p-tau217) | Pathological tau | Reduction |
| Neurofilament light (NfL) | Neurodegeneration | Potential reduction |

PET Imaging

• Amyloid PET: Baseline amyloid burden for patient selection
• Tau PET: Regional tau load and treatment effects
• FDG-PET: Glucose metabolism as neurodegeneration marker

Clinical Outcomes

Primary and secondary clinical endpoints:

• Cognitive tests: CDR-SB, ADAS-Cog13, MMSE
• Functional measures: ADCS-ADL
• Patient-reported outcomes: Quality of life measures

Rationale for MTBR Targeting

Evidence from Failed N-Terminal Antibodies

Previous anti-tau antibodies that targeted the N-terminus of tau all failed in Phase 2 trials:

Why N-Terminal Targeting Failed

Several hypotheses explain the failures:

Why MTBR Should Work Better

The MTBR targeting approach is more promising because:

Pharmacological Properties

Antibody Characteristics

• Isotype: Humanized IgG1
• Mechanism: Monoclonal antibody
• Affinity: High-affinity binding to pathological tau
• Selectivity: Preference for aggregated over monomeric tau

Pharmacokinetics

• Administration: Intravenous infusion
• Dosing interval: Monthly or less frequent dosing
• Half-life: Extended half-life enabling less frequent dosing
• Distribution: CNS penetration sufficient for target engagement

Safety Profile

Phase 1 Safety Results

The Phase 1 studies demonstrated:

• Generally well-tolerated: No significant safety signals
• No dose-limiting toxicity: Maximum tolerated dose not reached
• Infusion reactions: Manageable, generally mild
• No ARIA: Unlike anti-amyloid antibodies, no amyloid-related imaging abnormalities observed

Ongoing Monitoring

Long-term safety studies include:

• Regular MRI monitoring
• CSF safety biomarkers
• Adverse event tracking
• Immunogenicity assessment

Comparison with Other Tau-Targeting Approaches

Antibody Approaches

| Drug | Target | Epitope | Company | Phase | Notes |
|------|--------|---------|---------|-------|-------|
| E2814 | MTBR | p-tau396/404 | Eisai | Phase 2/3 | DIAN-TU |
| Bepranemab | MTBR | p-tau217 | UCB | Phase 2 | Different epitope |
| Semorinemab | N-terminus | Not applicable | Roche | Failed | First generation |
| Gosuranemab | N-terminus | Not applicable | Roche | Failed | First generation |

Other Modalities

| Approach | Example | Company | Stage |
|----------|---------|---------|-------|
| ASO | BIIB080 | Biogen/Ionis | Phase 2 |
| ASO | NIO752 | Roche | Phase 1 |
| Small molecule | LY3372689 | Eli Lilly | Phase 2 |
| Vaccine | ACI-35 | AC Immune | Phase 1/2 |

Future Directions

Potential Expansion Indications

E2814 could be evaluated in other tauopathies:

• Progressive Supranuclear Palsy (PSP): 4R-tauopathy
• Corticobasal Degeneration (CBD): 4R-tauopathy
• Frontotemporal Lobar Degeneration (FTLD): Various tau subtypes

Combination Strategies

Future development may include:

• Combination with anti-amyloid: Sequential or concurrent therapy
• Combination with other mechanisms: Multiple disease-modifying targets
• Earlier intervention: Pre-symptomatic treatment in at-risk populations

Clinical Significance

E2814 represents a potentially paradigm-shifting approach to tau-targeted therapy:

The success of E2814 would validate MTBR targeting as a viable strategy and potentially bring the first effective anti-tau therapy to patients.

See Also

• [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Pathology in AD](/mechanisms/tau-pathology-alzheimers)
• [DIAN-TU Study](/clinical-trials/dian-tu-001)
• [MAPT Gene](/genes/mapt)
• [Tau Protein](/proteins/tau)
• [Bepranemab](/clinical-trials/bepranemab-tau-antibody-alzheimers)

References